Arimipex 1 (Anastrozole)
Arimipex 1, manufactured by Sixpex USA Only, is a potent Aromatase Inhibitor (AI). It is primarily used to manage estrogen levels by inhibiting the enzyme responsible for converting androgens into estrogen.
Quick Facts
|
Feature |
Detail |
|
Active Ingredient |
Anastrozole (1 mg) |
|
Manufacturer |
Sixpex |
|
Administration |
Oral Tablet |
|
Half-Life |
40 to 50 hours |
|
Primary Use |
Postmenopausal breast cancer treatment |
|
Secondary Use |
Estrogen management during anabolic cycles |
Mechanism of Action
Arimipex 1 works by binding to the aromatase enzyme. This prevents the aromatization process, where the body converts testosterone into estradiol.
- In Medicine: It starves hormone-receptor-positive breast cancer cells of the estrogen they need to proliferate.
- In Bodybuilding: It prevents high levels of estrogen caused by exogenous testosterone, which can lead to unwanted side effects.
Common Usage & Dosage
Dosage is highly individual and should ideally be dictated by bloodwork (specifically Sensitive Estradiol testing).
- Standard Range: 0.5 mg to 1 mg.
- Frequency: Every other day (EOD) or every third day (E3D).
- Consistency: Should be taken at the same time each day, regardless of food intake.
Side Effects of Crushing Estrogen
Estrogen is often viewed as an "enemy" in fitness circles, but it is vital for male and female health. Reducing it too far (hypoestrogenism) leads to significant issues:
- Joint Health: Estrogen is neuroprotective and keeps joints lubricated. Low levels lead to "dry," painful joints and increased injury risk.
- Bone Density: Long-term suppression can lead to bone thinning and osteoporosis.
- Cardiovascular Health: Estrogen helps maintain healthy cholesterol levels; suppressing it can crash HDL (good cholesterol) and raise LDL (bad cholesterol).
- Mental Well-being: Low estrogen is frequently linked to lethargy, irritability, and a complete loss of libido.
Important Contraindications
- Pregnancy: Strictly prohibited as it can cause fetal harm.
- Premenopausal Women: Generally not indicated unless under strict oncological supervision.

